T cell-derived circulating DNA and tumour inflammatory microenvironment in EGFR-mutant advanced non-small cell lung cancer: Correlation with the outcome of EGFR TKI treatment

被引：0
|
作者：
Zungsontiporn, N. [1 ]
Santisukwongchote, S. [2 ]
Sitthideatphaiboon, P. [1 ]
Leelayuwatanakul, N. [3 ]
Korphaisarn, K. [4 ]
Chantranuwat, P. [2 ]
Sriuranpong, V. [1 ]
Vinayanuwattikun, C. [1 ]
机构：
[1] King Chulalongkorn Mem Hosp, Div Med Oncol, Dept Med, Thai Red Cross Soc, Bangkok, Thailand
[2] King Chulalongkorn Mem Hosp, Dept Pathol, Thai Red Cross Soc, Bangkok, Thailand
[3] King Chulalongkorn Mem Hosp, Div Pulm & Crit Care Med, Dept Med, Thai Red Cross Soc, Bangkok, Thailand
[4] Mahidol Univ, Siriraj Hosp, Div Med Oncol, Dept Med,Fac Med, Bangkok, Thailand
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2896
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
172P
引用
收藏
页码：S250 / S250
页数：1
相关论文
共 50 条
  • [1] Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer
    Cabanero, M.
    Tsao, M. S.
    CURRENT ONCOLOGY, 2018, 25 : S38 - S44
  • [2] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Kyoko Otsuka
    Akito Hata
    Jumpei Takeshita
    Chiyuki Okuda
    Reiko Kaji
    Katsuhiro Masago
    Shiro Fujita
    Nobuyuki Katakami
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
  • [3] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Otsuka, Kyoko
    Hata, Akito
    Takeshita, Jumpei
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Katakami, Nobuyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
  • [4] Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
    Ding, Jianghua
    Ding, Xingjing
    Zeng, Jiao
    Liu, Xiaoqun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [5] Role of T790M Mutation in EGFR-TKI Rechallenge for Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
    Zhang, Qiu-Yi
    Ke, E-E
    Deng, Wei
    Niu, Fei-Yu
    Zhao, Ning
    Su, Jian
    Chen, Zhi-Hong
    Yang, Jin-Ji
    Xu, Chong-Rui
    Yan, Hong-Hong
    Wu, Yi-Long
    Zhou, Qing
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S271 - S271
  • [6] Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome
    Remon, J.
    Moran, T.
    Reguart, N.
    Majem, M.
    Carcereny, E.
    Lianes, P.
    CANCER TREATMENT REVIEWS, 2014, 40 (06) : 723 - 729
  • [7] Prognostic value of EGFR genotype in EGFR-mutant non-small cell lung cancer
    Syrigos, Konstantinos
    Kotteas, Ilias
    Paraskeva, Maria
    Gkiozos, Ioannis
    Boura, Paraskevi
    Tsagouli, Sofia
    Grapsa, Dimitra
    Charpidou, Andriani
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [8] Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer
    Zhang, Chen
    Cao, Honggang
    Cui, Yanan
    Jin, Shidai
    Gao, Wen
    Huang, Chenjun
    Guo, Renhua
    THORACIC CANCER, 2021, 12 (19) : 2574 - 2584
  • [9] Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance
    Ding, Jianghua
    Ding, Xinjing
    Leng, Zhaohui
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (02) : 187 - 198
  • [10] Treatment outcomes of EGFR-TKI with or without locoregional brain therapy in advanced EGFR-mutant non-small cell lung cancer patients with brain metastases
    Linh, Do Mai
    Thinh, Tran Huy
    Hieu, Nguyen-Van
    Duc, Nguyen Minh
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2023, 27 (02): : 71 - 79
12345